Get access

Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine

Authors

  • M. Viganò,

    1. “A. M. and A. Migliavacca” Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Search for more papers by this author
  • P. Lampertico,

    1. “A. M. and A. Migliavacca” Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Search for more papers by this author
  • F. Facchetti,

    1. “A. M. and A. Migliavacca” Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Search for more papers by this author
  • G. Lunghi,

    1. Division of Hygiene, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Search for more papers by this author
  • M. Colombo

    1. “A. M. and A. Migliavacca” Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Search for more papers by this author

Pietro Lampertico, MD, PhD, 1st Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Via F. Sforza 35- 20122 Milan, Italy. E-mail: pietro.lampertico@unimi.it

Abstract

Summary.  Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day). The response to the increased dose of adefovir was compared with the response in 15 patients with a suboptimal response who did not receive an increase in the dose of adefovir. The increase in the dose of adefovir did not lead to a significant reduction in hepatitis B DNA when compared with patients maintained on the standard dose. These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response.

Ancillary